Observational studyBreast cancer research and treatment2026
Association of baseline tumor-infiltrating lymphocytes and cell-cycle regulation markers on prognosis and mortality in patients with advanced breast cancer according to tumor characteristics and treatment type: an observational study.
Observational study in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor proliferation and immune infiltration are key determinants of breast cancer biology, yet their prognostic value in the advanced setting remains incompletely defined. We evaluated the clinical relevance of tumor‑infiltrating lymphocytes (TILs) and four cell cycle regulation biomarkers-Ki67, MCM2, Cyclin A, and PHH3-across major breast cancer subtypes in a contemporary real‑world cohort.
methodsWe conducted a retrospective analysis of the outcomes of 398 patients with advanced breast cancer treated between 2020 and 2024. Clinicopathological variables were compared across HER2-/HR+, HER2+, and triple‑negative breast cancer (TNBC). Progression‑free survival (PFS) was assessed using Kaplan-Meier analysis and log‑rank tests. Multivariable polytomous logistic regression identified factors associated with PFS < 2 years. Subtype‑specific associations between TILs and PFS > 2 years were evaluated using multivariable Cox models adjusted for age, ECOG status, tumor grade, and prior therapies. Additional Cox regression models assessed predictors of overall survival (OS).
resultsLow TIL density was independently associated with early progression (RRR 2.28, 95% CI 1.19-4.03). Proliferation markers showed consistent associations with PFS: elevated Ki67, MCM2, Cyclin A, and PHH3 each correlated with shorter survival, with MCM2 showing the strongest effect. TIL-PFS associations were subtype‑dependent. In HR+/HER2 - disease, high TILs were linked to shorter PFS (HR 2.27, 95% CI 1.18-4.02), whereas in TNBC, low TILs predicted markedly worse outcomes (HR 2.33, 95% CI 1.88-2.86). TIL levels were not prognostic in HER2 + disease. Across all subtypes, high expression of Ki67, MCM2, Cyclin A, and PHH3 was significantly associated with reduced OS in multivariable models.
conclusionsSubtype‑specific immune infiltration and elevated proliferation activity are key predictors of disease trajectory in advanced breast cancer. TILs carry divergent prognostic meaning across subtypes, whereas proliferation markers consistently identify high‑risk disease. Integrating immune and proliferative biomarkers may enhance risk stratification and guide treatment tailoring, particularly within TNBC and hormonally driven tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.